Monograph Details
|
|
Immune System
> Immunization
|
|
TETANUS TOXOID BOOSTER |
| Manufacturer |
|
Sanofi Pasteur, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Tetanus vaccine. |
| Generic Name |
|
Tetanus toxoid booster vaccine; for IM or SC inj; contains thimerosal. |
| Indications |
|
Tetanus immunization booster. |
| Adults and Children |
|
<7yrs: not recommended. Give IM or SC in lateral mid-thigh or deltoid. ≥7yrs: After completion of primary immunization: 0.5mL every 10 years. Tetanus prophylaxis: see literature. |
| Contraindications |
|
Not for primary immunization. History of systemic allergic or neurologic reactions to a previous dose of DT. |
| Precautions |
|
Latex allergy. Previous arthus-type hypersensitivity reaction: do not give more frequently than every 10 years. Defer in moderate or severe active respiratory or other febrile infection (may vaccinate if mild or minor illness) or during polio outbreak. Bleeding disorders (use SC route). Immunosuppressed. History of Guillain-Barre syndrome within 6 weeks of last tetanus vaccine. Have epinephrine (1:1000) available. Elderly. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
May get suboptimal response with immunosuppressants (eg, chemotherapy, high dose corticosteroids ≥2 weeks, radiation); consider deferring. |
| Adverse Reactions |
|
Local reactions (eg, erythema, tenderness), malaise, fever, hypotension, pain, nausea, arthralgia; rare: neurological disorders. |
| How Supplied |
|
Vial (7.5mL)—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
